Gene regulation is central to all aspects of organism growth, and understanding it using large-scale functional datasets can provide a whole view of biological processes controlling complex phenotypic traits in crops. However, the connection between massive functional datasets and trait-associated gene discovery for crop improvement is still lacking. In this study, we constructed a wheat integrative gene regulatory network (wGRN) by combining an updated genome annotation and diverse complementary functional datasets, including gene expression, sequence motif, transcription factor (TF) binding, chromatin accessibility, and evolutionarily conserved regulation. wGRN contains 7.2 million genome-wide interactions covering 5947 TFs and 127 439 target genes, which were further verified using known regulatory relationships, condition-specific expression, gene functional information, and experiments. We used wGRN to assign genome-wide genes to 3891 specific biological pathways and accurately prioritize candidate genes associated with complex phenotypic traits in genome-wide association studies. In addition, wGRN was used to enhance the interpretation of a spike temporal transcriptome dataset to construct high-resolution networks. We further unveiled novel regulators that enhance the power of spike phenotypic trait prediction using machine learning and contribute to the spike phenotypic differences among modern wheat accessions. Finally, we developed an interactive webserver, wGRN (http://wheat.cau.edu.cn/wGRN), for the community to explore gene regulation and discover trait-associated genes. Collectively, this community resource establishes the foundation for using large-scale functional datasets to guide trait-associated gene discovery for crop improvement.
Download full-text PDF |
Source |
---|---|
http://dx.doi.org/10.1016/j.molp.2022.12.019 | DOI Listing |
Alzheimers Dement
December 2024
Karolinska Institute, Stockholm, Södermanland and Uppland, Sweden.
Background: Novel anti-amyloid therapies (AAT) for Alzheimer's Disease (AD) have recently been approved in the United States, Japan and China, and are under regulatory review in Europe. Questions remain regarding the long-term effectiveness and value of these drugs when used in routine clinical practice. Data from follow-up studies will be important to inform their optimal use, including criteria for treatment initiation, monitoring strategies, stopping rules, pricing and reimbursement considerations.
View Article and Find Full Text PDFBackground: Although investment in biomedical and pharmaceutical research has increased significantly over the past two decades, there are no oral disease-modifying treatments for Alzheimer's disease (AD).
Method: We performed comprehensive human genetic and multi-omics data analyses to test likely causal relationship between EPHX2 (encoding soluble epoxide hydrolase [sEH]) and risk of AD. Next, we tested the effect of the oral administration of EC5026 (a first-in-class, picomolar sEH inhibitor) in a transgenic mouse model of AD-5xFAD and mechanistic pathways of EC5026 in patient induced Pluripotent Stem Cells (iPSC) derived neurons.
Real-world data on the uptake, effectiveness and safety of new diagnostics and disease-modifying (DMT) treatments for Alzheimer's Disease (AD) are imperative. This can be achieved through patient registries. A major challenge is how to embed registry data capture into routine clinical practice.
View Article and Find Full Text PDFAlzheimers Dement
December 2024
Laboratory of Neuro Imaging (LONI), University of Southern California, Los Angeles, CA, USA.
Background: Anti-amyloid therapy appears to have an increased effect on reducing cognitive decline in amyloid- and tau-positive individuals. However, clinical trials inclusion criteria require solely amyloid positivity. Herein, we developed a machine-learning prediction model to identify tau positivity in amyloid-positive individuals using clinical variables.
View Article and Find Full Text PDFComb Chem High Throughput Screen
January 2025
Department of Emergency, First Medical Center of Chinese PLA General Hospital, 28 Fuxing Road, Beijing, 100853, China.
Background: The prevalence of depression in COVID-19 patients is notably high, disrupting daily life routines and compounding the burden of other chronic health conditions. In addition, to elucidate the connection between COVID-19 and depression, we conducted an analysis of commonly differentially expressed genes [co-DEGs], uncovering potential biomarkers and therapeutic avenues specific to COVID-19-related depression.
Methods: We obtained gene expression profiles from the Gene Expression Omnibus [GEO] database with strategic keyword searches ["COVID-19", "depression," and "SARS"].
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!